Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers

INTRODUCTION: We examined if a combination of proliferation markers and estrogen receptor (ER) activity could predict early versus late relapses in ER-positive breast cancer and inform the choice and length of adjuvant endocrine therapy. METHODS: Baseline affymetrix gene-expression profiles from ER-...

Descripción completa

Detalles Bibliográficos
Autores principales: Bianchini, Giampaolo, Pusztai, Lajos, Karn, Thomas, Iwamoto, Takayuki, Rody, Achim, Kelly, Catherine M, Müller, Volkmar, Schmidt, Marcus, Qi, Yuan, Holtrich, Uwe, Becker, Sven, Santarpia, Libero, Fasolo, Angelica, Del Conte, Gianluca, Zambetti, Milvia, Sotiriou, Christos, Haibe-Kains, Benjamin, Symmans, W Fraser, Gianni, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978752/
https://www.ncbi.nlm.nih.gov/pubmed/24060333
http://dx.doi.org/10.1186/bcr3481

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978752/
https://www.ncbi.nlm.nih.gov/pubmed/24060333
http://dx.doi.org/10.1186/bcr3481

Ejemplares similares